Timoney PJ, McCollum WH, Roberts AW, Murphy TW. variable, in that they range from persistent asymptomatic infections to respiratory disease, reproductive failure (abortion), and even fatal hemorrhagic fever (4,C7). EAV is the causative agent of equine viral arteritis (EVA) in horses, in which clinical signs can range from an asymptomatic infection to a flu-like illness in adult horses, abortion in pregnant mares, and interstitial pneumonia in neonatal foals (8, 9). Furthermore, in a variable percentage of stallions (10 to 70%), EAV can establish persistent infection in the reproductive tract, from which it is shed in semen for extended periods of time; carrier stallions are widely accepted to be the natural reservoir of the virus (9, 10). EAV infects equine endothelial cells, monocytes, macrophages, and a small subpopulation of CD3+ T cells (11,C13). In addition, the virus can replicate in a number of other mammalian cell types (including some human cells), suggesting that it may be capable of using more than one receptor molecule to gain entry into cells (13). In general, the process of viral entry into target cells is initiated by binding to a specific host cell receptor molecule(s) on the plasma membrane (14,C18). This interaction is a major determinant of viral tropism and pathogenesis. Currently, the cellular receptor(s) for EAV is not known, although previous studies have implicated the involvement of a heparin-like molecule in binding to rabbit kidney (RK-13) cells (19, 20). Interestingly, a recent genome-wide association study (GWAS) identified a region in equine chromosome 11 (ECA11; positions 49572804 to 49643932) with potential involvement in EAV infection and pathogenesis (8). Several genes within this region (e.g., CXCL16, HRNE, RABEP1, ARRB2) have structural properties that could enable them to participate in either the cell surface attachment or endocytosis of EAV. However, pathway analysis using Ingenuity Pathway Analysis (Ingenuity Systems Inc., Redwood City, CA) software and the PANTHER classification system (www.pantherdb.org) revealed that one of the candidate receptor molecules, equine CXCL16 (EqCXCL16), has scavenger receptor properties in common with CD163, an entry receptor of PRRSV (11, 14, 21, 22). Although the molecules are not structurally identical (23), the utilization of functionally comparable membrane-associated proteins by EAV and PRRSV represents a potentially interesting parallel between these two very closely related viruses, and as such, Taribavirin hydrochloride we hypothesized that EqCXCL16 could be one of the cellular receptors for EAV. This equine molecule has not been studied extensively; however, there is a considerable amount of published information concerning human CXCL16 (huCXCL16) (24, 25), which is a member of the CXC chemokine family. The human variant of this protein (huCXCL16) possesses a single transmembrane domain along with an intracellular SH2 binding Taribavirin hydrochloride domain and is expressed in both membrane-bound and soluble forms (26, 27). While soluble huCXCL16 can function as a chemokine, the membrane-bound form has scavenger receptor activity for phosphatidylserine and oxidized lipoprotein (SR-PSOX) (26, 28, 29). huCXCL16 is also involved in viral infections, arthritis, Taribavirin hydrochloride atherosclerosis, and the metastasis of certain cancers (25, 26, 30, 31). The analysis outlined in this report indicated that EqCXCL16 has a structural organization and functional properties very similar to those of its human counterpart, including the existence of membrane-bound and soluble forms. In this study, we unequivocally confirm that the transmembrane form of EqCXCL16 functions as Epha2 a cellular receptor for.